Pfizer sees ‘significant opportunity’ to increase COVID-19 vaccine costs

A top Pfizer executive noted a “significant opportunity” for higher prices for his COVID-19 vaccine when market forces driven by the pandemic enter a gradual shift.

“If you look at how current demand and current prices are being driven, this is clearly not being driven by what I will call normal market conditions, normal market forces,” said Frank D’Amelio, CFO of Pfizer, during a call. . “This was really driven by the pandemic state in which we live and by the needs of governments to really guarantee the doses of the various vaccine suppliers.”

Actions in this article

D’Amelio said that as the pandemic turns into a state called “endemic”, or when comprehensive vaccinations restrict recurrent diseases to certain pockets around the world, “normal market conditions will begin to appear”.

MODERN BEGINS TESTING THE COVID-19 VACCINE ON CHILDREN UNDER 12

“Factors such as efficacy, capacity for reinforcement, clinical utility will become basically very important and we see this, frankly, as a significant opportunity for our vaccine from the point of view of demand, from the point of view of prices, given the clinical profile of our vaccine “He continued, adding in part,” We think that as this changes from pandemic to endemic, we think there is an opportunity here for us. “

CLICK HERE TO GET FOX BUSINESS ON THE GO

The comments follow news of the launch of a company study to assess whether a third dose of its COVID-19 vaccine could increase effectiveness against coronavirus variants, such as one first detected in South Africa. During the call, D ‘ Amelio also noted an increasing likelihood of unique annual revaccination.